Evolent Health (NYSE:EVH) Might Have The Makings Of A Multi-Bagger
If you're looking for a multi-bagger, there's a few things to keep an eye out for. Amongst other things, we'll want to see two things; firstly, a growing return on capital employed (ROCE) and secondl
Express News | NYSE Order Imbalance 56214.0 Shares on Sell Side
RBC Capital Maintains Evolent Health(EVH.US) With Buy Rating, Maintains Target Price $42
RBC Capital analyst Sean Dodge maintains $Evolent Health(EVH.US)$ with a buy rating, and maintains the target price at $42.According to TipRanks data, the analyst has a success rate of 39.8% and a tot
Truist Financial Maintains Evolent Health(EVH.US) With Hold Rating
Truist Financial analyst Jailendra Singh maintains $Evolent Health(EVH.US)$ with a hold rating.According to TipRanks data, the analyst has a success rate of 29.9% and a total average return of -15.5%
Evolent Health To Acquire Machinify - Quick Facts
Express News | Evolent To Acquire Certain Assets Of Machinify And The Exclusive, Perpetual And Royalty-Free License Of Machinify Auth; Terms Not Disclosed
Express News | Evolent Health - Acquisition Is Immaterial to Evolent's Revenue Outlook and Is Estimated to Be Neutral to Adjusted Ebitda in First Year After Closing
Express News | Evolent Signs Agreement to Acquire Artificial Intelligence Utilization Management Products and Team From Machinify
Express News | NYSE Order Imbalance 82952.0 Shares on Buy Side
Shareholders Will Most Likely Find Evolent Health, Inc.'s (NYSE:EVH) CEO Compensation Acceptable
Express News | Evolent Health Inc : Guggenheim Cuts Target Price to $42 From $47
Express News | Shares of Health Insurers Are Trading Lower in Sympathy With UnitedHealth, Which Fell After Comments at the Bernstein 40th Annual Strategic Decisions Conference
Engaged Capital's Q1 Moves: Adds Envestnet, Trims Shake Shack, Others
Express News | NYSE Order Imbalance 89505.0 Shares on Buy Side
Analysts Have Conflicting Sentiments on These Healthcare Companies: Praxis Precision Medicines (PRAX), Iovance Biotherapeutics (IOVA) and Evolent Health (EVH)
Express News | Evolent Health Inc : Truist Securities Cuts Target Price to $28 From $34
Truist Adjusts Evolent Health's Price Target to $28 From $34, Notes Near-Term Lack of Claims Visibility; Keeps Hold Rating
Truist Adjusts Evolent Health's Price Target to $28 From $34, Notes Near-Term Lack of Claims Visibility; Keeps Hold Rating.
Evolent Health, Inc. (NYSE:EVH) Just Released Its First-Quarter Results And Analysts Are Updating Their Estimates
Last week, you might have seen that Evolent Health, Inc. (NYSE:EVH) released its first-quarter result to the market. The early response was not positive, with shares down 9.7% to US$24.46 in the past
Evolent Health First Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags
Evolent Health, Inc. (NYSE:EVH) Q1 2024 Earnings Call Transcript
No Data